The percentage of Americans taking GLP-1 drugs such as Ozempic or Zepbound to lose weight has nearly quadrupled since 2024, according to a new survey by Gallup. The pollsters find that 11% of U.S. adults say they currently take a GLP-1 medication, up from 3% in 2024, and 15% report that they have used the drugs for weight loss at some point.
Gallup’s survey also found that Americans’ obesity rate, based on calculations using self-reported height and weight, has dropped from a record high 39.9% in 2022 to 36.5% this year. Gallup’s Dan Witters calls that “a statistically meaningful decline that continues to inversely track with increased usage of GLP-1 medicine nationally.”
Meanwhile, the percentage of Americans who tell Gallup that they have been diagnosed with diabetes has leveled off since 2023 after 15 years of increases.
Nearly one in five GLP-1 users say they are taking a compounded or custom-mixed version of the drugs, with the lower cost fueling a shift away from brand-name versions, Gallup’s Witters writes.
The poll results are based on a web survey of 5,065 adults conducted from May 28 to June 5.